John had his bloodwork done today as he does every three weeks as required by the trial. Again, his thyroid function (THS) test is low. This is the third consecutive panel where it’s been low and the third time they’ve lowered his dosage of Synthroid from 100 mg to 75 mg and now to 50 mg.
He began taking Synthroid on May 2 when his THS came back high (6.99). The normal range is 0.50 to 4.50 mg. His next two panels came back in the normal range, but his last three have been low, lower and lowest.
I guess my question is-- since it seems extremely low--why wouldn’t the oncologist just discontinue the Synthroid rather than reducing dosage again? I mean in looking at his bloodwork, he’s only had one high reading.
I also can’t help but note the one high reading occurred after he had completed his HDIL2 treatments and wondering if that could have any bearing on that one high read.
Here are his numbers since first of year. Any thoughts?
THS (normal 0.50 – 4.50 mg)
1/03/12 – 3.44
1/31/12 - 3.50
2/16/12 – 2.14
5/2/12 – 6.99 HIGH
5/10/12 – 4.21
5/31/12 – 2. 27
6/20/12 - 0.18 LOW
7/11/12 – 0.05 LOW
8/1/12 – 0.3 LOW
Alice (caregiver for husband-John)
John – 63 Caucasian
Diagnosed: 10/14/11 Kidney cancer clear cell/grade 4/stage 4 – with sarcomatoid features and lung mets; also has soft tissue mass in shoulder area and pelvic area.
Symptoms: weight loss followed by cough
Surgeries: right nephrectomy - 11/1/11
Treatments to date:
January & February 2012 -HDIL2 treatment/first round 14 doses/2nd round 10 doses;
(discontinued after February 2012 as scan did not merit continuation)
5/10/2012 – BMS93558* Votrient trial (*formerly MDX1106)